We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Broccoli, Cauliflower May Help Suppress Hereditary Cancers

By Biotechdaily staff writers
Posted on 02 Jun 2006
A new study shows that specific vegetables—cauliflower and broccoli, in particular--have natural compounds that may decrease the risk of developing hereditary cancers. More...


A research team from Rutgers, The State University of New Jersey (New Brunswick, NJ, USA), has revealed that these widely eaten cruciferous vegetables--so called because their four-petal flowers look like crosses--are abundant in sulforaphane (SFN). This compound had earlier been shown to suppress some tumors in rodents induced by carcinogens, compounds external to the body. This study, however, centered on whether SFN might suppress the occurrence of hereditary cancers--those originating from an individual's genetic structure.

The American Cancer Society estimates that more than two-thirds of cancer may be prevented through lifestyle adaptations, and nearly one-third of these cancer occurrences can be attributed to diet alone. "Our research has substantiated the connection between diet and cancer prevention, and it is now clear that the expression of cancer-related genes can be influenced by chemopreventive compounds in the things we eat,” said Dr. Ah-Ng Tony Kong, a professor of pharmaceutics in the Ernest Mario School of Pharmacy at Rutgers.

Chemopreventive properties are those that prevent, block, or reverse the development of cancer. In a study published online in May 2006 in the journal Carcinogenesis, Dr. Kong and his colleagues utilized a mouse model for human colon cancer to demonstrate the chemopreventive abilities of SFN and explained how it functions to inhibit cancer at the biomolecular level.

The investigators used a specially bred strain of mice (labeled Apc/Min/+) that carry a mutation that switches off a gene (Apc) that inhibits tumors. This is the same gene known to be involved in the development of most colon cancers in humans. When the gene is inactivated in the mice, polyps, which lead to tumors, appear spontaneously in the small intestine. Studies using these mice can help in devising human clinical trials that can lead to new treatments for colon cancer in humans.

Two groups of mice were fed diets supplemented with SFN for three weeks, one group receiving 300 parts per million (ppm) of SFN and the other getting 600 ppm. "Our results clearly demonstrated that those mice fed with an SFN-supplemented diet developed significantly fewer and smaller tumors,” Dr. Kong said.

After the three weeks, the median number of polyps in the small intestine in each mouse decreased more than 25% in those on the 300 ppm diet and 47% in the 600 ppm treatment group, as compared to control animals who had received no SFN.

"Our results showed that SFN produced its cancer preventive effects in the mice by inducing apoptosis [programmed cell death] and inhibiting proliferation of the tumors; however, it was not clear what mechanism SFN employs to accomplish this,” Dr. Kong stated.

Utilizing biomarkers (indicator molecules) associated with apoptosis and proliferation, the researchers discovered that SFN suppressed certain enzymes or kinases that are highly expressed both in the mice and in patients with colon cancer. The researchers concluded that this enzymatic suppression activity is in all probability the basis for the chemopreventive effects of SFN.

"Our study corroborates the notion that SFN has chemopreventive activity. Based on these findings, we feel SFN should be evaluated clinically for its chemopreventive potential in human patients with Apc-related colon cancers,” Kong said.



Related Links:
Rutgers

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.